Cargando…
Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
Immune checkpoint inhibitors (ICIs), which can enhance antitumor immunity and inhibit cancer growth, have revolutionized the treatment of multiple cancers and dramatically decreased mortality. However, treatment with ICIs is directly associated with immune-related adverse events (irAEs) because of i...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599930/ https://www.ncbi.nlm.nih.gov/pubmed/34805229 http://dx.doi.org/10.3389/fmed.2021.762247 |
_version_ | 1784601042817646592 |
---|---|
author | Shen, Pan Deng, Xuan Hu, Zhishuo Chen, Zhe Huang, Yao Wang, Ke Qin, Kai Huang, Ying Ba, Xin Yan, Jiahui Han, Liang Tu, Shenghao |
author_facet | Shen, Pan Deng, Xuan Hu, Zhishuo Chen, Zhe Huang, Yao Wang, Ke Qin, Kai Huang, Ying Ba, Xin Yan, Jiahui Han, Liang Tu, Shenghao |
author_sort | Shen, Pan |
collection | PubMed |
description | Immune checkpoint inhibitors (ICIs), which can enhance antitumor immunity and inhibit cancer growth, have revolutionized the treatment of multiple cancers and dramatically decreased mortality. However, treatment with ICIs is directly associated with immune-related adverse events (irAEs) because of inflammation in off-target organs and autoimmunity resulting from non-specific immune activation. These irAEs can cause rheumatic diseases and manifestations such as inflammatory arthritis, polymyalgia rheumatica, myositis, vasculitis, Sicca and Sjogen's syndrome, and systemic lupus erythematosus. Early diagnosis and treatment of these adverse events will improve outcomes and quality of life for cancer patients. The treatment of rheumatic diseases induced by ICIs requires multidisciplinary cooperation among physicians. Furthermore, the underlying mechanisms are not fully understood and it is difficult to predict and evaluate these side effects precisely. In this review, we summarize available studies and findings about rheumatic irAEs, focusing mainly on the clinical manifestations, epidemiology, possible mechanisms, and guiding principles for treating these irAEs. |
format | Online Article Text |
id | pubmed-8599930 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85999302021-11-19 Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy Shen, Pan Deng, Xuan Hu, Zhishuo Chen, Zhe Huang, Yao Wang, Ke Qin, Kai Huang, Ying Ba, Xin Yan, Jiahui Han, Liang Tu, Shenghao Front Med (Lausanne) Medicine Immune checkpoint inhibitors (ICIs), which can enhance antitumor immunity and inhibit cancer growth, have revolutionized the treatment of multiple cancers and dramatically decreased mortality. However, treatment with ICIs is directly associated with immune-related adverse events (irAEs) because of inflammation in off-target organs and autoimmunity resulting from non-specific immune activation. These irAEs can cause rheumatic diseases and manifestations such as inflammatory arthritis, polymyalgia rheumatica, myositis, vasculitis, Sicca and Sjogen's syndrome, and systemic lupus erythematosus. Early diagnosis and treatment of these adverse events will improve outcomes and quality of life for cancer patients. The treatment of rheumatic diseases induced by ICIs requires multidisciplinary cooperation among physicians. Furthermore, the underlying mechanisms are not fully understood and it is difficult to predict and evaluate these side effects precisely. In this review, we summarize available studies and findings about rheumatic irAEs, focusing mainly on the clinical manifestations, epidemiology, possible mechanisms, and guiding principles for treating these irAEs. Frontiers Media S.A. 2021-11-04 /pmc/articles/PMC8599930/ /pubmed/34805229 http://dx.doi.org/10.3389/fmed.2021.762247 Text en Copyright © 2021 Shen, Deng, Hu, Chen, Huang, Wang, Qin, Huang, Ba, Yan, Han and Tu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Shen, Pan Deng, Xuan Hu, Zhishuo Chen, Zhe Huang, Yao Wang, Ke Qin, Kai Huang, Ying Ba, Xin Yan, Jiahui Han, Liang Tu, Shenghao Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy |
title | Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy |
title_full | Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy |
title_fullStr | Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy |
title_full_unstemmed | Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy |
title_short | Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy |
title_sort | rheumatic manifestations and diseases from immune checkpoint inhibitors in cancer immunotherapy |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599930/ https://www.ncbi.nlm.nih.gov/pubmed/34805229 http://dx.doi.org/10.3389/fmed.2021.762247 |
work_keys_str_mv | AT shenpan rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy AT dengxuan rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy AT huzhishuo rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy AT chenzhe rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy AT huangyao rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy AT wangke rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy AT qinkai rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy AT huangying rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy AT baxin rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy AT yanjiahui rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy AT hanliang rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy AT tushenghao rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy |